Iothalamate Pregnancy and Breastfeeding Warnings
Brand names: Conray, Conray-30, Conray-400, Conray-43, Cysto-Conray, Cysto-Conray II
Iothalamate Pregnancy Warnings
Use is not recommended unless clearly needed.
US FDA pregnancy category: B
Intravascular contrast agents may cross the placenta and can potentially produce transient fetal hypothyroidism. Reproduction studies in animals have revealed no evidence of impaired fertility or harm to the fetus. There are no adequate and well controlled studies in pregnant women.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Iothalamate Breastfeeding Warnings
Breastfeeding is not recommended during use of this drug.
Excreted into human milk: Yes (unchanged)
Comments:
-The effects in the nursing infant are unknown.
-Use bottle feeding for 24 hours following the administration of this drug.
See also
References for pregnancy information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2015) "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc
References for breastfeeding information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2015) "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
